ABSTRACT
Immune-checkpoint inhibitors (ICIs) are reshaping the prognosis of many cancer types and are progressively becoming a standard of care for many of them. Cancer immunotherapy has started a revolution in the oncology therapeutic landscape, bringing new hope to patients but also a whole new spectrum of toxicities for practitioners to manage. Oncologists and specialists involved in the pluridisciplinary management of immune-related adverse events (irAEs) are increasingly confronted with the therapeutic challenge of severe and/or refractory cases. In this personal view, we summarize the therapeutic strategies reported to manage them. Based on current knowledge of irAE pathogenesis and our immunological expertise, we also transpose the use of new biologic and non-biologic immunosuppressive agents, used to treat primary autoimmune disorders (AIDs), in the context of severe and/or steroid refractory irAE management. Depending on the immune-type predominant infiltrate, we propose a personalized treatment algorithm beyond corticosteroids. A shut-off strategy, intended to treat severe or steroid-refractory irAEs, based on the efficient inhibition of key inflammatory components involved in their pathophysiological processes, and limit potential adverse effects of drug immunosuppression on tumor response is proposed. This approach goes beyond current guidelines, challenging the step-by-step increase in drug immunosuppression proposed so far. constitutes also a new challenge as the related toxicities often involve multiple organs and occur at higher frequencies compared to monotherapy. For example, the prospective Checkmate 067 trial on ipilimumab/nivolumab combination in advanced melanoma reported a 4% incidence of patients with steroid-refractory irAEs. 1 The spectrum of organ systems affected by irAEs is very broad and their management often requires expertise that goes beyond the specialty of oncology. They vary in frequency and severity, depending on the agent(s) and the affected system(s). Consequently, their optimal management requires experienced multidisciplinary teams. Extensive knowledge in the field of clinical immunology and immunosuppressive therapy, going beyond current guidelines, is often required of such teams. Another crucial challenge is the need for early recognition and prompt treatment of irAEs to avoid adverse outcomes due to delayed patient care. Like most treatment-related toxicities in oncology, irAEs should be managed according to grade.
INTRODUCTION
Nevertheless, one should not overlook the limitations of current grading systems, and thus should not to substitute them for clinical judgment, especially in frail patients and when confronted with rapidly evolving irAEs. In this personal view, we discuss personalized therapeutic options for severe and/or refractory irAEs, based on current immunopathophysiological knowledge and on extrapolations from primary autoimmune counterparts.
High-quality guidelines regarding the management of irAEs were released by the European Society of Medical Oncology (ESMO) 2 , the National Comprehensive Cancer Network (NCCN) and the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. 3, 4 They provide treatment algorithms for most frequent irAEs in a comprehensive way and detail their recommendation regarding the use of immunosuppressive drugs according to irAE severity and duration. They also emphasize the importance of avoiding delays in the work-up to rule-out other differential diagnoses (e.g., infectious complications or tumor progression) before initiating effective immunosuppressive therapy. However, as exhaustive as these guidelines can be, they are still limited regarding the management of severe and/or refractory irAEs, with which clinicians are confronted in the day-to-day practice. Retrospective data on a large ipilimumab-treated cohort reported that more than one-third of patients received corticosteroids to manage an irAE, and one-third of those required additional immunosuppressive drugs. 5 It is important to be aware that rare yet life-threatening irAEs are constantly reported, representing a diagnostic and therapeutic challenge; for such irAEs, evidence to guide management recommendations is limited due to the scarcity of literature, consisting of only small series or case reports. Some experts are already adopting a first instance cytokine-directed therapy, such as tocilizumab (an IgG1 humanized anti-IL6R mAb), in steroid-refractory cases.
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NEW THERAPEUTIC PERSPECTIVES TO MANAGE ICI-INDUCED TOXICITIES
Due to the scarcity of prospective trials regarding drug immunosuppression in the setting of high-grade irAEs, in daily clinical practice one draws from small series, case reports and expert opinion to handle challenging cases. Current guidelines promote a step-by-step approach, starting with high-dose steroids and increasing drug immunosuppression as needed. This consensus will certainly be maintained in the absence of validated clinical or biological biomarkers predictive of steroid-refractoriness. On the other hand, clinicians confronted with severe irAEs should not discard the possibility to add a cytokine-directed mAb from the beginning of a severe irAE with the putative advantage of "shutting-off" early a rapidly evolving immuno-pathophysiological process, thereby avoiding patient exposure to extended courses of immunosuppression. A good example for first instance aggressive drug immunosuppression is myocardial irAEs. In this case, better efficacy of rapid immunosuppression is presumed due to its fulminant clinical presentation, the high associated morbi-mortality rate, as well as the documented increased risk of adverse outcomes with lower steroid doses compared to high-dose therapy. 7 A recent meta-analysis revealed an incidence of fatalities surrounding 1% in ICI treated patients. 8 These severe irAEs tended to occur early after treatment initiation with monotherapy (with a median of forty days) and even earlier with ICI combination (with a median of two weeks). Unusual clinical presentations along with diagnosis delays surged as mortality contributing factors.
Biomarker-based approaches are already being explored and will certainly help therapeutic decision. For example, in ICI-related colitis, ulcerative endoscopic finding have recently been suggested as predictive surrogate markers for steroid-refractoriness. 9 A recent study on 90 colic biopsies from patients with ICI-related colitis showed different profiles of immune infiltrates: 27% of patients had immune infiltrates with predominant intraepithelial lymphocytosis, whereas 73% of patients had predominant monocytic/neutrophilic infiltrates. 9 Not to mention that transposing therapeutic knowledge from primary autoimmune disorders is also hampered by the different nature of irAEs in terms of disease phenotype, response to treatment and pathophysiological mechanisms. For example, a histologic analysis conducted on liver biopsies showed a more diffuse, cytotoxic T-cell predominant, and lobular infiltrate pattern in comparison to autoimmune hepatitis (AIH), altogether with less CD4 T-cells and plasma cells in the parenchyma. 10 The lack of steroid efficacy in AIH in comparison to most ICI related hepatitis signs also a clear-cut difference highlighting the possible implication of CD4 T-cells in steroid refractoriness. 11 Multidrug-refractory cases of severe hepatitis have been treated with anti-thymocyte antiglobulin (ATG), reflecting the relative resistance to selective immunosuppression of this particular irAE. 12, 13 Another contrasting example is the one of ICI-related myasthenia gravis (MG) where a higher risk of crisis compared to their autoimmune counterparts, as well as an increased association with myositis has been reported. 14, 15, 16 In the opposite, ICI-related colitis displays some interesting common features with inflammatory bowel disease (IBD). Both of these disorders demonstrate sensitivity to anti-TNFα mAbs and share as well histological and pathophysiological features. The latter is highlighted by the link between IBD and certain CTLA4 polymorphisms in the population. 17 Even though the chronic nature of IBD tends to disrupt the epithelial layer and show granulomatous lesions as characteristic features, a lymphocytic-neutrophilic infiltrate is a shared histologic feature.
In light of the present lack of validated biomarkers, immunopathological patterns could be considered as rational target tools to personalize a shut-off strategy ( Knowledge extrapolated from solid organ transplant patients treated with ICIs supports a significant impact of calcineurin inhibitors (CNI) and mycophenolate mofetil (MMF) on the T-cell response. Even so, the latter is already advised as second line immunosuppressive drugs in current guidelines. However, in our opinion, they should be avoided in immunogenic tumors, especially if a curative intent is at stake, such as in advanced melanoma patients.
Knowing the role of IL-6 as a major acute inflammatory phase mediator, in cytotoxic T-cells differentiation, but also its protumor properties, an IL-6 targeting strategy constitutes a robust substitute to older immunosuppressive drugs, without compromising the efficacy of immunotherapy. 18, 19 Limitations of such strategies regarding their cost and financial impact on health care systems should be acknowledged. Nevertheless, if the strategy is effective, such costs might be amortized thanks to decreased morbidity. In any case, they should be considered in light of the already high costs ensuing from ICI therapies. Prospective clinical trials answering these open questions are urgently advocated, due to the rapid expansion of cancer immunotherapy.
Nevertheless, most of these toxicities are so rare that clinical trials are almost inconceivable.
This is why it is essential to actively report irAEs to competent national authorities and to publish them in the medical literature, along with empirically treated cases and case series.
The following section provides an overview of standard and off-label agents used to treat severe/refractory irAEs as an adjunct to corticosteroids. In principle, we propose to continue each such therapy until the complete resolution of the respective irAE (Table 1) .
Corticosteroids
By virtue of to their rapid action and convenient use, corticosteroids are still considered the first-line treatment of severe irAEs. Commonly used regimens comprise oral prednisone (1 to 2 mg/kg) or parenteral methylprednisolone (bolus range of 125 to 1000 mg). High-dose corticosteroids carry an inherent risk of infectious complications and metabolic disturbances (iatrogenic Cushing's syndrome), and therefore weaning should be started at early signs of recovery. However, a tapering period of four to six weeks is advocated to avoid flare phenomena relative to the long half-life of ICI mAbs.
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Calcineurin inhibitors (CNI), azathioprine (AZA), mycophenolate mofetil (MMF) and anti-TNFα therapies
Treatments used for IBD and AIH have been used by extrapolation to treat colitis and hepatitis resulting from checkpoint blockade. Severe and refractory irAE colitis can be treated with infliximab (a chimeric monoclonal anti-TNFα antibody) at a single dose of 5 mg/kg, by analogy with Crohn's disease 20 . This treatment has been shown to be highly effective for corticosteroid-refractory colitis, with rapid responses occurring in 1 to 3 days. In some relapsing cases, a second dose is necessary after 2 weeks. Maintenance treatment should be reserved for chronic and relapsing cases. Infliximab is also advocated in steroidrefractory pneumonitis, although with very heterogenous successes reported in the literature. 21 Nevertheless, anti-TNFα therapy seems a better alternative than older IS drugs in this indication. As one of the most frequent irAEs during anti-PD-1/PD-L1 therapies, steroidrefractory pneumonitis lacks tremendously of evidence-based therapeutic approaches. This frail population is also frequently subjected to unfortunate long courses of steroids as pneumonitis often demonstrates steroid-dependency. Etanercept, adalimumab, certolizumab and golimumab are also available and could be alternatives to infliximab given their excellent safety profiles and proven effectiveness. A published case of corticosteroid-and methotrexate-refractory ICI-induced polyarthritis treated with adalimumab revealed excellent symptomatic improvement together with clinical regression of joint inflammation. 22 Infliximab is also a rescue option in the treatment of refractory AIH, suggesting that this is another reasonable indication for the other anti-TNFα agents. 23 A special caution in using anti-TNFα mAbs to treat irAEs is also advocated by the rare cases of paradoxical adverse events reported under these treatments. In the literature, these encompass mostly the emergence or aggravation of psoriasis, IBD, lung granulomatous disease and uveitis, but the full spectrum of rarer paradoxical AEs is even wider. 24 MMF is considered a second-line treatment for ICI-induced hepatitis and is also advocated by most current guidelines as a second-line therapy based on a relatively low level of evidence;
by analogy with AIH, azathioprine could also be a reasonable treatment option. 20 CNI have been used as adjunct treatment for corticosteroid-refractory colitis and hepatitis, although evidence supporting their use in this setting is not well documented. 26 A case of infliximabrefractory enterocolitis has also demonstrated a rapid improvement after two weeks of cyclosporine. Perhaps a focus on its ability to potentially prevent myocardial fibrosis should also be brought to the attention of clinicians and be addressed in surviving cohorts of ICIinduced myocarditis. 27 Plasma dosing and levels-based scheduling of MMF and CNI administration should be performed in order to confirm the therapeutic doses and avoid toxicity.
Beyond the aforementioned tested immunosuppressive/immunomodulatory drugs to treat severe/refractory irAE cases, additional options can be envisaged by extrapolating knowledge from the treatment of primary AIDs (Figure 1 ).
Anti-IL-1 blockade
IL-1 is one of the main cytokines present during the acute phase of inflammation. Preclinical data have identified the IL-1beta pathway as an important promoter of tumor progression through stimulation of tumor-associated macrophages (TAMs), myeloid suppressive cells and up-regulation of PD-L1 in tumor cells. 28 In addition, CNS injury leads to an inflammatory response that is partly mediated by an increase in IL-1 levels through tissue infiltration by neutrophils. 26 As shown in several animal models, IL-1 receptor antagonists possess CNSprotective properties. 29 Preclinical studies pointed out the central role of IL-1 in autoimmune encephalitis, through its effect on the differentiation of IL-17 producing T-cells. 30 It is also a mediator of T-cell adhesion to brain microvasculature in certain blood-brain barrier preclinical models. 31 .Anakinra, a recombinant IL-1 receptor antagonist, and canakinumab, a monoclonal antibody with anti-IL-1beta activity, are approved for the treatment of rheumatoid arthritis and other auto-inflammatory diseases, respectively. IL-1 blockade is accepted as having no detrimental effect on cancer response. 32 An anti-IL-1 strategy employing anakinra or canakinumab may find a place as primary therapy for some irAEs, such as acute phase MG, encephalitis, aseptic meningitis, severe arthritis, chronic inflammatory demyelinating polyradiculoneuritis (CIDP), psoriasis, auto-inflammatory diseases, or severe anti-TNFα-refractory colitis, pneumonitis and myocarditis. A possible protocol could be anakinra 100 mg once/day or canakinumab 300-600 mg every 8 weeks.
Anti-IL-6 blockade
Together with IL-1 and TNFα, one of main cytokines in the acute inflammation phase is IL-6. Additionally, IL-6 has been reported to promote cancer development and metastasis, and to function as a main cytokine in the generation of a systemic inflammatory response and the expansion of cancer-related symptoms, leading to the deterioration in physical performance and quality of life. 33 Furthermore, anti-IL-6 therapy appears to be very effective for severe IBD that does not respond to traditional therapy targeting TNFα.
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Consequently, the use of anti-IL-6 therapy as an upfront treatment could be an excellent alternative to anti-TNFα or anti-IL-1 agents for many irAE indications, without compromising the efficacy of immunotherapy. Serum IL-6 has proven to be a useful marker of rheumatoid arthritis disease activity. 35 However, elevated serum levels of IL-6 are frequent in cancer patients. 36 Nevertheless, a baseline IL-6 level assessment before ICI therapy followed by repeated measurements in case of irAE emergence could still be a useful biomarker. A serious caution is advocated in interpreting these results, as they can also sign tumor progression or an infectious complication. The elevation of serum IL-6 should not be considered a decisive factor in the introduction of anti-IL-6 therapy, as it has not been validated in dedicated clinical trials. A prospective trial planning to assess the efficacy of first-line tocilizumab treatment in ICI-induced colitis and arthritis is about to initiate (NCT03601611). Amongst other measurements, the levels of IL-6 and CRP will be taken in 
Anti-IL-17 therapy
High IL-17 serum levels have been reported during ipilimumab-induced colitis. 45 Blockade through monoclonal antibodies such as secukinumab may constitute an interesting strategy to manage this toxicity. However, contradictory evidence regarding IL-17 and its implications in promoting tumor growth and metastasis has raised concern. 46 For example, a patient with metastatic colon cancer (with a mismatch repair-deficient tumor) who initially responded to PD-1 blockade, showed tumor progression after treatment with secukinumab for a psoriatic rash. 47 In view of the heterogeneous microenvironment across tumor types and individuals, the identification of profiles that might be able to predict the role of IL-17 in tumor control or, conversely, tumor promotion should be pursued. Possible indications for use of anti-IL-17 therapy are severe psoriasis refractory to anti-TNFα therapy and rheumatoid arthritis. Several mAbs are available and could be used as follows: ixekizumab 80 mg s.c. every two weeks, brodalumab 210 mg s.c. every two weeks and secukinumab 150 mg s.c. every week.
Anti-IL-23/12 therapy
Ustekinumab is a mAb targeting the common p40 subunit of IL-23 and IL-12. It is approved for the treatment of cutaneous psoriasis and related arthritis. A randomized trial comparing ustekinumab to placebo in the setting of anti-TNFα-refractory Crohn's disease showed that one-third of patients experienced a response at 6 weeks. 48 Opposing roles of IL-23 and IL-12 in maintaining outgrowth and dormancy of tumors in mice raise concerns regarding the use of ustekinumab in cancer patients. Nevertheless, most clinical trials did not find an unexpected increase in cancer rates across approved indications. 49, 50 In the palliative and refractory irAE setting, ustekinumab treatment may be a conceivable option in selected cases.
A possible protocol is: induction dose of 6 mg/kg i.v. followed by 90 mg every 8 to 12
weeks.
Anti-integrin 4
Natalizumab is an anti-integrin 4 antibody that is approved for the treatment of multiple sclerosis. It has also been used in a relapsing case of limbic encephalitis in a patient with stage IV SCLC, leading to cognitive improvement without impairing a durable tumor response with a combined checkpoint inhibition. 51 Vedolizumab is an anti-integrin α4β7
antibody showing in gut-selective anti-inflammatory activity, with indication for the treatment of refractory IBD. 52 Its efficacy has been reported in a case-series of seven steroidrefractory cases of ICI-induced colitis, obtaining a remission in six patients. Two to four vedolizumab administrations seemed enough to obtain steroid-free remission in their cohort, with no adverse side-effect of vedolizumab reported. 53 
Janus kinase inhibition
Tofacitinib, a Jak 1/3 inhibitor, is currently used across several rheumatological indications, such as refractory rheumatoid arthritis and ulcerative colitis. 54 On the other hand, some reports suggest that the risk of lower GI tract perforation associated with tofacitinib treatment among rheumatoid arthritis patients may be more common than with other anti-TNFα agents, suggesting the need for close clinical follow-up during the treatment of ICI-induced colitis. 43 A possible dosing scheme could be 5 mg or 10 mg twice per day.
Anti-B-cell strategy
As the major role of T cells is well established in the pathogenesis of irAEs, yet several studies have also reported a possible contributive role of B-cells, especially in skin irAEs (with bullous phenotype) and endocrine irAEs (e.g. in hypophysitis and thyroiditis). [55] [56] [57] Recently, a first report described peripheral blood changes in B-cell number and qualitative sub-populations in melanoma patients treated with ICIs. 58 ; in other cases, such antibodies were undetectable. In several reports, both type of cases (i.e. independently of serologic status), showed an impressive neurologic improvement after treatment with rituximab (anti-CD20 monoclonal antibody); in these cases, patients were mostly unresponsive to corticosteroids and IVIGs. 63, 65 Thus, whether autoantibodies are directly pathogenic (i.e., anti-NMDAR), directed against intra-cytoplasmic antigens (i.e., anti-Hu), or undetectable, rituximab can be considered as a therapeutic alternative, with probably low impact on tumor control. Additionally, rituximab could be an excellent option for ICIinduced AIDs with an autoantibody profile, such as SLE, severe SJS, ANCA-associated vasculitis, cutaneous vasculitis, autoimmune autonomic ganglionopathy (AAG), sensory ganglionopathy, nephritis, MG, transverse myelitis, enteric neuropathy and encephalitis.
Furthermore, rituximab can also be used to treat autoimmune hepatitis or refractory hemolytic anemia in patients intolerant or refractory to standard regimens. 66 Interestingly, tumor-associated B-cells in melanoma have been implicated in drug resistance and to detain a pro-tumorigenic property in part through IGF-1 secretion. 67 CD20 is also aberrantly expressed in subsets of melanoma cells with stem cell properties and is being studied as a target antigen for chimeric antigen receptor T-cell therapy (CART). 68 A pilot study including ten patients with therapy-resistant melanoma showed an activity of B-cell depletion with ofatumumab in eight of them, thus suggesting at least a good safety profile regarding this kind of immunosuppression on tumor control. Encouraging data from case-series have also been published showing median survival exceeding one year in multi-treated metastatic melanoma patients receiving rituximab. 69 Possible protocols are two courses of rituximab 1 g two weeks apart or 375 mg/m 2 once per week for 4 weeks. Other fully human anti-CD20
antibodies are also available: ofatumumab 300 mg on day 1 and 1000 mg on day 2, obinutuzumab 1000 mg on days 1 and 2, and ocrelizumab 300 mg on days 1 and 4. Because these new human anti-CD20 antibodies seem to have an excellent safety profile and at least similar effectiveness as rituximab, they may provide a possible alternative to rituximab.
Belimumab (anti-BAFF mAb) has proven its efficacy in SLE and may be an option as an adjunct to rituximab in severe/refractory autoantibody-mediated irAEs, as this combination may induce a more profound B-cell depletion by acting on plasma cells activation. 70 Thereby, it remains important to define the best combination B-cells therapy as well as the appropriate sequence.
A possible deleterious effect on tumor control should lead to a careful assessment of patient's risk and potential benefits.
Intravenous immunoglobulins (IVIGs) and plasmapheresis
IVIGs are the standard treatment for Guillain-Barré syndrome (GBS) as well as subacute and CIDP. Dramatic improvements in ICI-induced cases of GBS or CIPD have been reported using standard approaches with protocols of 400 mg/kg/day for 5 days. 71 Immune thrombocytopenia is a rare irAE whose occurrence may cause delays in the instauration of further anticancer treatment and place the patient at life-threatening risk for bleeding, especially in populations with a high prevalence of CNS metastasis, such as melanoma patients. Three-quarters of patients will respond to corticosteroids; refractory cases may require CNI treatment or IVIGs. 72 Thrombopoietin agonists such as romiplostim have also been used in the setting of anti-PD-1-induced thrombocytopenia. 73 Use of IVIGs should be limited in view of their intense, albeit short-lasting, effect. Possible indications for IVIGs are GBS, subacute and chronic inflammatory neuropathies, immune thrombocytopenia, facial nerve palsy, MG, transverse myelitis, enteric neuropathy, ocular myositis and encephalitis. 74 A case of severe corticosteroid-refractory autoimmune neutropenia responding to IVIG following ipilimumab treatment has also been reported. 75 A possible protocol might be 400 mg/kg/day for 5 days once per month for a total of 3 to 4 treatments.
A case of MG crisis showed a favorable outcome for at least 6 months after methylprednisolone, IVIGs and 5 courses of plasmapheresis. 15 As the treatment backbone of GBS relies on the latter, corticosteroid-refractory immune-related AIDP and/or encephalitis patients could be considered as potential candidates for plasmapharesis.
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Cyclophosphamide (CP)
Despite its carcinogenic risk, a pulse of CP may be very useful as an induction treatment for remission in multiple severe irAEs, such as symptomatic sarcoidosis, steroid-refractory pneumonitis, GBS, severe SJS with central and neurological symptoms, AAG, sensory ganglionopathy, polyneuropathy and central neuritis. An induction protocol is CP (10 to 15 mg/kg) at weeks 0, 2, 4, 7, 10 and 13 (cumulative dose of ~7 g) or 500 mg every two weeks for a total of 6 cures, similar to its use for SLE nephritis.
Cyclophosphamide-rituximab
In order to achieve rapid remission with minimal exposure to the carcinogenic risk of CP, an appropriate alternative protocol to 6 CP cures could comprise 4 administrations of rituximab (375 mg/m 2 ) at weeks 0, 1, 2 and 3 and two administrations of CP (10 to 15 mg/kg) at weeks 0 and 2.
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CONCLUSION
The development of cancer immunotherapy is one of the major medical breakthroughs. We are only at the beginning of a new era and we are still learning how to make the best use of these novel potent therapies in the management of cancer patients. We have however been 
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FM wrote the manuscript and prepared the figures and tables; MO conceived the review, wrote the manuscript and prepared the figures and tables. All authors wrote, commented on and corrected the manuscript. weeks, a third line should be considered. For that, we propose an anti-integrin 4 agent (Natalizumab) as a first choice; if not available, then a non-selective IS or a Janus Kinase inhibitor could also be considered. If no improvement is observed after the second administration repeated after two weeks, a fourth line could be considered, such as cyclophosphamide 10-15 mg/kg and/or plasmapheresis. The fourth line could be repeated more than twice until irAE resolution. The administration of IVIG could be considered for GBS and CDIP at any moment.
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